Eli Lilly (LLY) Short-term Investments (2009 - 2025)

Eli Lilly (LLY) has reported Short-term Investments for 17 consecutive years, with $121.6 million the latest figure, recorded in Q3 2025.

• Short-term Investments for Q3 2025 came in at $121.6 million, down 18.61% year-over-year; the trailing twelve-month figure through Sep 2025 was $121.6 million (down 18.61% YoY), and the FY2024 annual result was $154.8 million, up 41.89% from the prior year.
• Short-term Investments was $121.6 million for Q3 2025 at Eli Lilly, down from $170.1 million in the prior quarter.
• Over five years, Short-term Investments peaked at $170.1 million in Q2 2025 and troughed at $37.1 million in Q3 2021.
• Average Short-term Investments over 5 years is $115.3 million, with a median of $123.4 million recorded in 2023.
• The widest YoY moves for Short-term Investments: up 272.31% in 2021, down 37.5% in 2021.
• Over 5 years, Short-term Investments stood at $90.1 million in 2021, then surged by 60.71% to $144.8 million in 2022, then declined by 24.65% to $109.1 million in 2023, then surged by 41.89% to $154.8 million in 2024, then declined by 21.45% to $121.6 million in 2025.
• Per Business Quant data, the three most recent Short-term Investments figures were $121.6 million in Q3 2025, $170.1 million in Q2 2025, and $127.4 million in Q1 2025.